진행성 비소세포폐암의 예후에 있어 FDG-PET의 중요성에 대한 연구

키워드

참고문헌 (21)

1. 2002 Annual report of the Korea Central Cancer registry, "Ministry of Health and Welfare", ~ (2003)
2. 2004 Annual report on the cause of death statistics, "Korea National Statistic Office", ~ (2005)
3. Devita VT, "Cancer: principles and practice of oncology. 7th ed", pp.793~ (2005), Lippincott Williams & Wilkins
4. Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
5. Hoang T, "Clinical model to predictsurvival in chemonaive patients with advanced non-small-cell-lung cancer treated with third-generation chemotherapy regimen based on eastern cooperative oncology group data", J Clin Oncol, 23, pp.175~183 (2005)
6. Paesmans M, "Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party", J Clin Oncol, 13, pp.1221~1230 (1995)
7. Vansteenkiste JF, "Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group", J Clin Oncol, 17, pp.3201~3206 (1999)
8. Kostakoglu L, "18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma", J Nucl Med, 44, pp.224~239 (2003)
9. fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy, "J Clin Oncol", 2002, 1398~1404
10. MacManus MP, "High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy", Int J Radiat Oncol Biol Phys, 50, pp.287~293 (2001)
11. MacManus MP, "F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non small cell lung carcinoma: powerful correlation with survival and high impact on treatment", Cancer, 92, pp.886~895 (2001)
12. Ryu JS, "FDGPET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology", Lung Cancer, 35, pp.179~187 (2002)
13. fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment, "Lung Cancer", 2003, 151~157
14. MacManus MP, "Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with nonsmall-cell lung cancer", J Clin Oncol, 21, pp.1285~1292 (2003)
15. Duhaylongsod FG, "Lung tumor growth correlates with glucose metabolism measured by fluoride-18-fluorodeoxyglucose positron emission tomography", Ann Thorac Surg, 60, pp.1348~1352 (1995)
16. Younes M, "Overexpression of Glut1 and Glut3 in stage I non small cell lung carcinoma is associated with poor survival", Cancer, 80, pp.1046~1051 (1997)
17. Gatenby RA, "The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models", Cancer Res, 63, pp.3847~3854 (2003)
18. Higashi K, "18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer", J Nucl Med, 43, pp.39~45 (2002)
19. fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer, "J Clin Oncol", 2005, 1136~1143
20. fluorodeoxyglucose uptake by positron emission tomography, "Clin Cancer Res", 2000, 3837~3844
21. Hoang JK, "Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma", J Clin Oncol, 26, pp.1459~1464 (2008)

관련 논문AI추천